ERC Starting Grant · 2021
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPR
Hematopoietic stem cells (HSCs) reside in the bone marrow where they throughout life sustain continuous blood production through a controlled balance of differentiation and self-renewal. Transplantation of HSCs from a healthy person can replace a defective hematopoietic system of a patient thereby curing the patient for life. HSCs have found increasing therapeutic application, e.g. in hematologic malignancies and hematopoietic genetic disorders. This applies not only to the allogeneic transplantation setting but also to the autologous setting where advances in genetic engineering technologies have enabled autologous gene therapies. However, major challenges remain in both settings…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.